|
1
|
Farber LJ, Furge K and Teh BT: Renal cell
carcinoma deep sequencing: recent developments. Curr Oncol Rep.
14:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reuter VE: The pathology of renal
epithelial neoplasms. Semin Oncol. 33:534–543. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Itsumi M and Tatsugami K: Immunotherapy
for renal cell carcinoma. Clin Dev Immunol. 2010:2845812010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walsh N, Larkin A, Kennedy S, et al:
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and
ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 9:62009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Linehan WM, Rubin JS and Bottaro DP: VHL
loss of function and its impact on oncogenic signaling networks in
clear cell renal cell carcinoma. Int J Biochem Cell Biol.
41:753–756. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Linehan WM, Pinto PA, Srinivasan R, et al:
Identification of the genes for kidney cancer: opportunity for
disease-specific targeted therapeutics. Clin Cancer Res.
13:671s–679s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
An J and Rettig MB: Mechanism of von
Hippel-Lindau protein-mediated suppression of nuclear factor kappa
B activity. Mol Cell Biol. 25:7546–7556. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peruzzi B, Athauda G and Bottaro DP: The
von Hippel-Lindau tumor suppressor gene product represses oncogenic
β-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci
USA. 103:14531–14536. 2006.PubMed/NCBI
|
|
9
|
Conrad PW, Freeman TL, Beitner-Johnson D
and Millhorn DE: EPAS1 trans-activation during hypoxia requires
p42/p44 MAPK. J Biol Chem. 274:33709–33713. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:3362003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Horikawa Y, Wood CG, Yang H, et al: Single
nucleotide polymorphisms of microRNA machinery genes modify the
risk of renal cell carcinoma. Clin Cancer Res. 14:7956–7962. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trang P, Weidhaas J and Slack F: MicroRNAs
as potential cancer therapeutics. Oncogene. 27(Suppl 2): S52–S57.
2008. View Article : Google Scholar
|
|
15
|
Didiano D and Hobert O: Perfect seed
pairing is not a generally reliable predictor for miRNA-target
interactions. Nat Struct Mol Biol. 13:849–851. 2006. View Article : Google Scholar
|
|
16
|
Yao J, Liang L, Huang S, et al:
MicroRNA-30d promotes tumor invasion and metastasis by targeting
Galphai2 in hepatocellular carcinoma. Hepatology. 51:846–856.
2010.PubMed/NCBI
|
|
17
|
Hand NJ, Master ZR, Eauclaire SF,
Weinblatt DE, Matthews RP and Friedman JR: The microRNA-30 family
is required for vertebrate hepatobiliary development.
Gastroenterology. 136:1081–1090. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bruchova H, Merkerova M and Prchal JT:
Aberrant expression of microRNA in polycythemia vera.
Haematologica. 93:1009–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schlaeger C, Longerich T, Schiller C, et
al: Etiology-dependent molecular mechanisms in human
hepatocarcinogenesis. Hepatology. 47:511–520. 2008. View Article : Google Scholar
|
|
21
|
Tang X, Muniappan L, Tang G and Ozcan S:
Identification of glucose-regulated miRNAs from pancreatic (beta)
cells reveals a role for miR-30d in insulin transcription. RNA.
15:287–293. 2009. View Article : Google Scholar
|
|
22
|
Marton S, Garcia MR, Robello C, et al:
Small RNAs analysis in CLL reveals a deregulation of miRNA
expression and novel miRNA candidates of putative relevance in CLL
pathogenesis. Leukemia. 22:330–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Visone R, Pallante P, Vecchione A, et al:
Specific microRNAs are downregulated in human thyroid anaplastic
carcinomas. Oncogene. 26:7590–7595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu C, Jin B, Chen L, et al: MiR-30d
induces apoptosis and is regulated by the Akt/FOXO pathway in renal
cell carcinoma. Cell Signal. 25:1212–1221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Petillo D, Kort EJ, Anema J, Furge KA,
Yang XJ and Teh BT: MicroRNA profiling of human kidney cancer
subtypes. Int J Oncol. 35:109–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakada C, Matsuura K, Tsukamoto Y, et al:
Genome-wide microRNA expression profiling in renal cell carcinoma:
significant down-regulation of miR-141 and miR-200c. J Pathol.
216:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Juan D, Alexe G, Antes T, et al:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pantuck AJ, Seligson DB, Klatte T, et al:
Prognostic relevance of the mTOR pathway in renal cell carcinoma.
Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rathmell WK and Chen S: VHL inactivation
in renal cell carcinoma: implications for diagnosis, prognosis and
treatment. Expert Rev Anticancer Ther. 8:63–73. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Redova M, Svoboda M and Slaby O: MicroRNAs
and their target gene networks in renal cell carcinoma. Biochem
Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Esposito F, Tornincasa M, Pallante P, et
al: Down-regulation of the miR-25 and miR-30d contributes to the
development of anaplastic thyroid carcinoma targeting the polycomb
protein EZH2. J Clin Endocrinol Metab. 97:E710–E718. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen LZ, Niu XH, Han XL, Xie BS and Mao
ZB: Down-regulation of miR-30d on proliferation of HeLa cells.
Chinese Journal of Biochemistry and Molecular Biology.
11:1047–1052. 2009.
|
|
33
|
Kumar M, Lu Z, Takwi AA, et al: Negative
regulation of the tumor suppressor p53 gene by microRNAs. Oncogene.
30:843–853. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu Y, Ryan SL, Elliott DJ, et al:
Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and
KHDRBS3 at 8q24.22–q24.23 in medulloblastoma. PLoS One.
4:e61592009.PubMed/NCBI
|
